These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 28049654)

  • 1. Histone Lysine Demethylase Inhibitors.
    Jambhekar A; Anastas JN; Shi Y
    Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 28049654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.
    Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M
    ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
    Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
    Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting histone lysine methylation in cancer.
    McGrath J; Trojer P
    Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of histone demethylases in cancer therapy.
    Hoffmann I; Roatsch M; Schmitt ML; Carlino L; Pippel M; Sippl W; Jung M
    Mol Oncol; 2012 Dec; 6(6):683-703. PubMed ID: 22902149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future therapeutic potential of histone demethylases: A critical analysis.
    Natoli G; Testa G; De Santa F
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cadmium induces histone H3 lysine methylation by inhibiting histone demethylase activity.
    Xiao C; Liu Y; Xie C; Tu W; Xia Y; Costa M; Zhou X
    Toxicol Sci; 2015 May; 145(1):80-9. PubMed ID: 25673502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
    Li L; Li R; Wang Y
    Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing histone demethylase inhibitors in cells: lessons learned.
    Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
    Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Suzuki T
    Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1.
    Zhou C; Wu F; Lu L; Wei L; Pai E; Yao Y; Song Y
    PLoS One; 2017; 12(2):e0170301. PubMed ID: 28158205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
    Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
    Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Histone Lysine Demethylase LSD1/KDM1A as a New Avenue for Cancer Therapy.
    Fang Y; Liao G; Yu B
    Curr Top Med Chem; 2019; 19(11):889-891. PubMed ID: 31389779
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances and challenges in understanding histone demethylase biology.
    Nowak RP; Tumber A; Johansson C; Che KH; Brennan P; Owen D; Oppermann U
    Curr Opin Chem Biol; 2016 Aug; 33():151-9. PubMed ID: 27371875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the development of histone lysine demethylase inhibitors.
    Maes T; Carceller E; Salas J; Ortega A; Buesa C
    Curr Opin Pharmacol; 2015 Aug; 23():52-60. PubMed ID: 26057211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
    Wu F; Zhou C; Yao Y; Wei L; Feng Z; Deng L; Song Y
    J Med Chem; 2016 Jan; 59(1):253-263. PubMed ID: 26652247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends of LSD1 inhibitors in viral infections.
    Zwergel C; Stazi G; Mai A; Valente S
    Future Med Chem; 2018 May; 10(10):1133-1136. PubMed ID: 29787289
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting Histone Methylation in Cancer.
    McCabe MT; Mohammad HP; Barbash O; Kruger RG
    Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.